Zalcitabine

Zalcitabine , also called dideoxycytidine, is a nucleoside analog reverse transcriptase inhibitor sold under the trade name Hivid®. The recommended dosage is 0.750 mg every 8 hours, as part of a combination regimen.Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus . (From the Wikpedia article Zalcitabine.)

Download PDF

Recent Publications on Zalcitabine:
Structural studies of nucleoside analog and feedback inhibitor binding to Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. The Drosophila melanogaster multisubstrate deoxyribonucleoside kinase...	10th July, 2008	Department of Molecular Biology, Swedish University of Agricultural	FEBS J. 2008 May;275(9):2151-60. Epub 2008 Apr 1. DOI Direct Link
Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. To elucidate the mechanisms underlying peripheral neuropathic pain in the...	9th July, 2008	Pain Research Group, Department of Anaesthetics, Pain Medicine and	Eur J Pain. 2008 Jul 5;. DOI Direct Link
Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. BACKGROUND: A total of 8.3 million HIV-positive people live in the...	2nd July, 2008	Department of Infectious Diseases, Alfred Hospital, Commercial Road,	Neurology. 2008 Jul 1;71(1):50-6. DOI Direct Link
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. BACKGROUND: Peripheral neuropathy (PN) in HIV-infected individuals is...	1st July, 2008	Centre for Sexual Health and HIV Research, University College London,	Antivir Ther. 2008;13(2):289-95.
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells. 2',2'-Difluorodeoxycytidine (gemcitabine), a pyrimidine nucleoside analog,...	25th June, 2008	Section of Clinical Pharmacology, Department of Medicine, Dartmouth	Hum Exp Toxicol. 2007 Dec;26(12):911-21. DOI Direct Link
→View more research publications.

Zalcitabine Clinical Trials:
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine	HIV Infections

Zalcitabine Patents:
US Patent No.	Title
7354934	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
7368531	Human secreted proteins
7371388	Treatment of Sjogren's syndrome by administration of TR18 polypeptides
7371772	Bicyclic compound, production and use thereof
7371822	Human G-protein coupled receptor variant of HM74, HGPRBMY74
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Zalcitabine scientists - we have details of around 129 individuals working on Zalcitabine .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.